Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
VMPL
Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication.
Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment1, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.2
The announcement marks a significant advancement in management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need.
Speaking on the occasion, Mr. Aurelien Breton, Managing Director, Servier India, said, "Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India."
IDH1 mutation occurs in approximately 7-14% of AML patients in India3, making targeted mechanisms especially relevant for this subset.
"This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.", highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India.
Speaking on the importance of treatment access, Ms. Pratima Tripathi, Commercial Director, Servier India, said: "Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients."
By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patients.
Disclaimer: This press release is intended solely to share regulatory and medical information regarding the launch; the reference to "Tibsovo" is not intended as a promotional or public advertisement. Use of the therapy is strictly based on a doctor's prescription and clinical discretion.
About Servier India
Servier India has been committed for over three decades to delivering innovative pharmaceutical solutions that improve the lives of patients and their families across India. Established in 1985 as an affiliate of the leading independent French pharmaceutical Servier Group, the company focuses on therapeutic areas such as Cardiometabolism, Neuroscience, Venous Diseases, and Oncology. Servier India has a strong pan-India presence and a dedicated workforce of around 580 that strives to address critical healthcare challenges with passion and purpose.
As part of Servier group operating in over 150 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation. Globally, Servier invests heavily in research and development, focusing on our key therapeutic areas.
About Servier
Servier is a global pharmaceutical group governed by a Foundation that aspires to serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiometabolism and venous diseases, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. Headquartered in France, Servier relies on a strong geographical footprint; its medicines are available in close to 140 countries.The group achieved a revenue of EUR5.9 billion in 2024.
Additional Details on Ivosidenib
Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy.
In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
French scientists find new blood type in Guadeloupe woman
Basse-Terre: A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed "Gwada negative," France's blood supply agency has announced. The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on Friday. "The EFS has just discovered the 48th blood group system in the world!" the agency said in a statement on social network LinkedIn. "This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT)." The scientific association had until now recognised 47 blood group systems . Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a "very unusual" antibody was first found in the patient in 2011. However, resources at the time did not allow for further research, he added. Scientists were finally able to unravel the mystery in 2019 thanks to " high-throughput DNA sequencing ", which highlighted a genetic mutation, Peyrard said. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said. This woman "is undoubtedly the only known case in the world," said the expert. "She is the only person in the world who is compatible with herself," he said. Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene. The name "Gwada negative", which refers to the patient's origins and "sounds good in all languages", has been popular with the experts, said Peyrard. The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing the discovery of new blood groups has accelerated in recent years. Peyrard and colleagues are now hoping to find other people with the same blood group. "Discovering new blood groups means offering patients with rare blood types a better level of care," the EFS said. cre-tmt-as/yad
The Hindu
5 hours ago
- The Hindu
French scientists find new blood type in Guadeloupe woman
A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed "Gwada negative," France's blood supply agency has announced. The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on Friday. "The EFS has just discovered the 48th blood group system in the world!" the agency said in a statement on social network LinkedIn. "This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT)." The scientific association had until now recognised 47 blood group systems. Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a "very unusual" antibody was first found in the patient in 2011. However, resources at the time did not allow for further research, he added. Scientists were finally able to unravel the mystery in 2019 thanks to "high-throughput DNA sequencing", which highlighted a genetic mutation, Peyrard said. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said. This woman "is undoubtedly the only known case in the world," said the expert. "She is the only person in the world who is compatible with herself," he said. Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene. The name "Gwada negative", which refers to the patient's origins and "sounds good in all languages", has been popular with the experts, said Peyrard. The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing the discovery of new blood groups has accelerated in recent years. Peyrard and colleagues are now hoping to find other people with the same blood group. "Discovering new blood groups means offering patients with rare blood types a better level of care," the EFS said.
Time of India
7 hours ago
- Time of India
Scientists may have found a way to extend lifespan without strict dieting; here's what the research shows
For centuries, humanity has pursued the secret to a longer life through alchemy, mythology, and, more recently, science. While the philosopher's stone remains a myth, researchers have discovered a reliable method to extend lifespan in animals: eating less. Tired of too many ads? go ad free now Known as dietary restriction , this practice triggers biological mechanisms that slow aging and improve longevity. However, strict dieting is difficult and unsustainable for many. The pressing question now is whether we can replicate these benefits without giving up the joy of food. Could science develop treatments that mimic the effects of calorie restriction, offering a longer, healthier life—without constant hunger? Can a pill help you live longer without dieting? Science says maybe In the last decade, researchers have studied molecules that imitate the biological impacts of eating less. Two of the most researched compounds are rapamycin and metformin. These compounds hold the promise of increasing lifespan without the physiological and psychological strain of constant dieting. A new study led by researchers in the compared the impact of these drugs to that of dietary restriction. The findings were illuminating rapamycin showed life-extending effects nearly as consistent as eating less, while metformin did not produce the same longevity benefits. Why eating less works so well Dietary restriction has been the gold standard of anti-ageing research, when researchers first learned that laboratory rats fed a lower-calorie diet lived longer than their normally fed counterparts. Since then, many more have established that consuming fewer calories through portion control or intermittent fasting is able to extend life in a range of different species. Nonetheless, strict dieting is hard to keep to, and too much restriction will cause harm to one's health. Tired of too many ads? go ad free now That is why scientists are keen to discover alternatives that provide the same benefits with fewer drawbacks. How Rapamycin and Metformin became anti-aging contenders Rapamycin, which was initially identified in Easter Island soil in the 1970s, is a potent immunosuppressant drug utilised to suppress organ transplant rejection. Its anti-aging applications result from its capacity to inhibit a primary molecular switch (mTOR) that informs cells that nutrients are abundant. By suppressing this message, rapamycin mimics the action of dietary deprivation at the cell level. Actually, a combination of rapamycin with another medication, trametinib, has been found to further prolong the lifespan of mice. Metformin is a compound found in the French lilac plant that is commonly prescribed to manage blood sugar levels in individuals with type 2 diabetes. Like rapamycin, it targets the body's nutrient-sensing mechanisms. With its extensive record of safety and widespread use, it's been a potential life-extending candidate. Yet the review of 167 studies involving eight vertebrate animals—from fish to rats—found no persistent evidence that metformin prolonged lifespan. This would indicate it might not be able to deliver all the benefits of dietary restriction, at least singly. Which works best: Eating less or taking a pill? Three interventions in the research: Dietary restriction (reducing intake) Rapamycin Metformin And the results were unequivocal: Dietary restriction is still the most persistent way to increase lifespan. Rapamycin stands close second, with promising results in several species and both sexes. Metformin, as it happens, failed to produce consistent benefits. According to the research, this places rapamycin among the most exciting leads in the quest for effective anti-ageing treatments. The future of aging is promising—but still experimental Though aging is not a disease, it is the main risk factor for most chronic diseases, such as cancer, dementia, and cardiovascular disease. Slowing aging—albeit modestly—may result in healthier longer lives and lower healthcare expenditures, particularly as populations globally become older. All that said, some cautionary results should be noted. A few studies actually indicated shortened lifespan with rapamycin or dietary restriction. And the majority of studies have been conducted in lab animals not humans. Co-lead researcher Dr. Edward Ivimey-Cook from the University of Glasgow emphasized, 'While our findings don't advocate for widespread Rapamycin use just yet, they do reinforce the need for continued research into its potential for promoting healthy aging . This also opens up broader conversations around the development of longevity-focused treatments.' Supporting this view, Dr. Sultanova noted, 'Our results highlight drug repurposing as a promising strategy for enhancing both healthspan and lifespan.' Both Rapamycin and Metformin are currently undergoing human clinical trials, with definitive results yet to be released. *Disclaimer: This article is intended for informational purposes only and should NOT be interpreted as medical advice. While current research on drugs like rapamycin and metformin shows potential in extending lifespan in animal models, these findings are NOT yet conclusive for humans. Always consult a qualified healthcare professional before considering any medical treatment or lifestyle change related to longevity or disease prevention. Also Read |
